Shots: The companies collaborated to accelerate the discovery and development of novel therapies for patients with cancer indications.M2GEN will provide valuable patient-consented, de-identified clinical and genomic data to support Merck’s […]readmore
Shots: Redx to receive $10M as up front followed by another $10M in year two and will receive up to $400M as milestones along with royalties on sales of the […]readmore
Shots: Cyclica to receive up front, milestones upon completion of specific stages for Project Nexus. AUM to get right to develop & commercialize therapies resulting from Project Nexus The collaboration […]readmore
Shots: Merck KGaA to utilize Personalis’ cancer immunogenomics platform, ImmunoID NeXT to evaluate novel biomarkers and mechanisms of resistance to cancer therapies The collaboration leads to the development of novel […]readmore
Shots: The US FDA announces Project Orbis, an initiative of the FDA Oncology Center of Excellence (OCE) providing a framework concurrent submission and review of oncology therapies in collaboration with […]readmore
Copyright © 2020 Digiqole. All Right Reserved.